Angad Chhabra, n/a

Senior Director, Clinical Operations
Axsome Therapeutics, Inc

Poster(s):

• (58) Efficacy and Safety of Symbravo® (MoSEICTM meloxicam and rizatriptan) in Participants With Migraine Experiencing an Inadequate Response to Oral CGRP Inhibitors: Topline Results From the EMERGE Trial
  Wednesday, October 29, 2025